Identifying NOTCH signaling-specialized hematopoietic supportive subpopulation from mesenchymal stem cells

Human umbilical cord mesenchymal stem cells (UC-MSCs) are widely studied as a promising cellular therapy for a variety of diseases due to their accessible sources, less of ethical concerns, and capacities for immunomodulation and tissue repair. However, cellular heterogeneity arising during in vitro expansion imposes challenges in quality control for clinical applications and transform, requiring further investigation. Two fetal umbilical cords were obtained from Sinogene C&G Stem Cells Co., Ltd. Primary UC-MSCs were isolated and subjected to continuous in vitro passaging culture. The harvested cells were sorted for single-cell RNA sequencing. A total of 78,178 cells and 14 subpopulations were screened for downstream bioinformatic analysis. Experimental validation was performed through both in vitro cell assays and in vivo animal studies. Mid-passage UC-MSCs showed more favorable functional performance, based on differential gene expression and functional enrichment analysis. Furthermore, we obtained an optimal subpopulation (C8) during clinical-grade cell culture by holistic evaluation of stemness, hematopoietic support capacity, and immunomodulatory potential. The stemness maintenance of C8 subpopulation was closely associated with NOTCH signaling pathway, as identified by cell–cell communication network analysis. Further analyses established NOTCH2 as the dominant receptor mediating NOTCH signaling in UC-MSCs. Notably, we identified MLPH and LPXN as signature markers specifically enriched in the C8 subpopulation. MLPH high LPXN high UC-MSCs displayed higher hematopoietic support and immunosuppression capabilities compared to MLPH low LPXN low UC-MSCs. Mid-passage UC-MSCs demonstrate favorable characteristics for clinical applications. The UC-MSC subpopulation with high NOTCH signaling activity exhibits enhanced hematopoietic support and immunosuppressive capabilities. MLPH and LPXN serve as ideal markers for isolating this functionally subpopulation.

Authors

Institutions

Publication Details

Journal
Stem Cell Research & Therapy
Published
2026-06-16
DOI
https://doi.org/10.1186/s13287-026-05095-1
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Identifying NOTCH signaling-specialized hematopoietic supportive subpopulation from mesenchymal stem cells

Linping Hu, Xuemei Peng, Y P Zhang, M He et al.
Stem Cell Research & Therapy
Mesenchymal stem cell research
article

Identifying NOTCH signaling-specialized hematopoietic supportive subpopulation from mesenchymal stem cells

Linping Hu, Xuemei Peng, Y P Zhang, M He, Yangjia Cao, Tao Cheng
article en

Abstract

Human umbilical cord mesenchymal stem cells (UC-MSCs) are widely studied as a promising cellular therapy for a variety of diseases due to their accessible sources, less of ethical concerns, and capacities for immunomodulation and tissue repair. However, cellular heterogeneity arising during in vitro expansion imposes challenges in quality control for clinical applications and transform, requiring further investigation. Two fetal umbilical cords were obtained from Sinogene C&G Stem Cells Co., Ltd. Primary UC-MSCs were isolated and subjected to continuous in vitro passaging culture. The harvested cells were sorted for single-cell RNA sequencing. A total of 78,178 cells and 14 subpopulations were screened for downstream bioinformatic analysis. Experimental validation was performed through both in vitro cell assays and in vivo animal studies. Mid-passage UC-MSCs showed more favorable functional performance, based on differential gene expression and functional enrichment analysis. Furthermore, we obtained an optimal subpopulation (C8) during clinical-grade cell culture by holistic evaluation of stemness, hematopoietic support capacity, and immunomodulatory potential. The stemness maintenance of C8 subpopulation was closely associated with NOTCH signaling pathway, as identified by cell–cell communication network analysis. Further analyses established NOTCH2 as the dominant receptor mediating NOTCH signaling in UC-MSCs. Notably, we identified MLPH and LPXN as signature markers specifically enriched in the C8 subpopulation. MLPH high LPXN high UC-MSCs displayed higher hematopoietic support and immunosuppression capabilities compared to MLPH low LPXN low UC-MSCs. Mid-passage UC-MSCs demonstrate favorable characteristics for clinical applications. The UC-MSC subpopulation with high NOTCH signaling activity exhibits enhanced hematopoietic support and immunosuppressive capabilities. MLPH and LPXN serve as ideal markers for isolating this functionally subpopulation.

Stem Cell Research & Therapy
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Institute of Hematology & Blood Diseases Hospital (CN), Guangzhou Medical University Cancer Hospital (CN), Guangzhou Medical University (CN)
Openalex Percentile: Top 10%
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.